|
|
||||||||||
|
J Am Coll Cardiol, 2001; 38:1718-1724 © 2001 by the American College of Cardiology Foundation |





* Cardiology Division, University of Calgary, Calgary, Alberta, Canada
Cardiovascular Division, Brigham and Womens Hospital, Boston, Massachusetts, USA
Cardiology Division, University of California at Irvine, Irvine, California, USA
Cardiovascular Section, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA
|| Cardiology Division, Case Western Reserve University, Cleveland, Ohio, USA
¶ Cardiovascular Division, University of Florida, Gainesville, Florida, USA
# Department of Biostatistics, University of Washington, Seattle, Washington, USA
** Division of Cardiology, Oregon Health Sciences University, Portland, Oregon, USA

Cardiology Division, the Cleveland Clinic Foundation, Cleveland, Ohio, USA
Manuscript received February 7, 2001; revised manuscript received May 29, 2001, accepted August 8, 2001.
* Correspondence: Dr. D. George Wyse, University of Calgary, 3330 Hospital Drive, Northwest, Calgary, Alberta, T2N 4N1 Canada. Reprint requests: AVID Clinical Trial Center, 1107 NE 45th Street, Suite 505, Seattle, Washington 98105 USA
dgwyse{at}ucalgary.ca
OBJECTIVES
This study evaluated the prognosis of patients resuscitated from ventricular tachycardia (VT) or ventricular fibrillation (VF) with a transient or correctable cause suspected as the cause of the VT/VF.
BACKGROUND
Patients resuscitated from VT/VF in whom a transient or correctable cause has been identified are thought to be at low risk for recurrence and often receive no primary treatment for their arrhythmias.
METHODS
In the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial, patients with a potentially transient or correctable cause of VT/VF were not eligible for randomization. The mortality of these patients was compared with the mortality of patients with a known high risk of recurrence of VT/VF in the AVID registry.
RESULTS
Compared with patients having high risk VT/VF, those with a transient or correctable cause for their presenting VT/VF were younger and had a higher left ventricular ejection fraction. These patients were more often treated with revascularization as the primary therapy, more commonly received a beta-blocker, less often required therapy for congestive heart failure and less commonly received either an antiarrhythmic drug or an implantable cardioverter defibrillator. Nevertheless, subsequent mortality of patients with a transient or correctable cause of VT/VF was no different or perhaps even worse than that of the primary VT/VF population.
CONCLUSIONS
Patients identified with a transient or correctable cause for their VT/VF remain at high risk for death. Further research is needed to define truly reversible causes of VT/VF. Meanwhile, these patients may require more aggressive evaluation, treatment and follow-up than is currently practiced.
| ||||||||||||||||
This article has been cited by other articles:
![]() |
L. H. Curtis, S. M. Al-Khatib, A. M. Shea, B. G. Hammill, A. F. Hernandez, and K. A. Schulman Sex Differences in the Use of Implantable Cardioverter-Defibrillators for Primary and Secondary Prevention of Sudden Cardiac Death JAMA, October 3, 2007; 298(13): 1517 - 1524. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Passman and A. Kadish Sudden Death Prevention With Implantable Devices Circulation, July 31, 2007; 116(5): 561 - 571. [Full Text] [PDF] |
||||
![]() |
L. R.C. Dekker, C. R. Bezzina, J. P.S. Henriques, M. W. Tanck, K. T. Koch, M. W. Alings, A. E.R. Arnold, M.-J. de Boer, A. P.M. Gorgels, H. R. Michels, et al. Familial Sudden Death Is an Important Risk Factor for Primary Ventricular Fibrillation: A Case-Control Study in Acute Myocardial Infarction Patients Circulation, September 12, 2006; 114(11): 1140 - 1145. [Abstract] [Full Text] [PDF] |
||||
![]() |
Developed in Collaboration With the European Heart, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) J. Am. Coll. Cardiol., September 5, 2006; 48(5): 1064 - 1108. [Full Text] [PDF] |
||||
![]() |
Developed in Collaboration With the European Heart, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) J. Am. Coll. Cardiol., September 5, 2006; 48(5): e247 - e346. [Full Text] [PDF] |
||||
![]() |
D. P. Zipes, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death--executive summary: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Eur. Heart J., September 1, 2006; 27(17): 2099 - 2140. [Full Text] [PDF] |
||||
![]() |
Writing Committee Members, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Europace, September 1, 2006; 8(9): 746 - 837. [Full Text] [PDF] |
||||
![]() |
R. Parkash, A. Tang, G. Wells, J. Blackburn, I. Stiell, C. Simpson, P. Dorian, R. Yee, D. Cameron, S. Connolly, et al. Use of implantable cardioverter defibrillators after out-of-hospital cardiac arrest: a prospective follow-up study Can. Med. Assoc. J., October 26, 2004; 171(9): 1053 - 1056. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. P. van Alem, M. G.W. Dijkgraaf, J. G.P. Tijssen, and R. W. Koster Health System Costs of Out-of-Hospital Cardiac Arrest in Relation to Time to Shock Circulation, October 5, 2004; 110(14): 1967 - 1973. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Sterk, A.P. van Alem, R. Tukkie, T.A. Simmers, and R.W. Koster ICD-implantation guidelines versus clinical practice: a prospective study of out-of-hospital cardiac arrest survivors Europace, January 1, 2004; 6(3): 179 - 183. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. DiMarco Implantable Cardioverter-Defibrillators N. Engl. J. Med., November 6, 2003; 349(19): 1836 - 1847. [Full Text] [PDF] |
||||
![]() |
A. E. Buxton The Clinical Use of Implantable Cardioverter Defibrillators: Where Are We Now? Where Should We Go? Ann Intern Med, March 18, 2003; 138(6): 512 - 514. [Full Text] [PDF] |
||||
![]() |
Think Twice Before Attributing Life-Threatening Arrhythmias to Transient or Correctable Causes Journal Watch Cardiology, January 11, 2002; 2002(111): 6 - 6. [Full Text] |
||||
![]() |
S. Viskin, A. Halkin, and J. E. Olgin Treatable causes of sudden death: not really "treatable" or not really the cause? J. Am. Coll. Cardiol., November 15, 2001; 38(6): 1725 - 1727. [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |